In vivo CAR-T engineering: insights from the 2025 ASH annual meeting - PubMed
5 hours ago
- #Cancer immunology
- #CAR-T therapy
- #ASH meeting
- In vivo CAR-T engineering involves reprogramming endogenous T-cells into CAR-T cells using vectors.
- Viral and nonviral platforms presented at the 2025 ASH meeting enable precise T-cell targeting and efficient CAR expression.
- Preclinical models showed robust CAR-T cell generation, effective tumor clearance, and strong clinical potential.
- Current limitations need addressing in future research.
- Key findings, translational challenges, and future directions were discussed at the meeting.